Home Lifestyle & Health Positive Interim Analysis of Phase 3 Study: MSD and Ridgeback’s Investigational Oral Antiviral Molnupiravir Reduced the Risk of Hospitalization or Death by Approximately 50% for Patients with Mild or Moderate COVID-19